Neurodegenerative diseases are characterized by a progressive deterioration of central and peripheral neural functions resulting from evolving pathological insults to neurons and/or glial cells in brain, spinal cord and peripheral nerves, leading to neuron death. Neurodegenerative diseases have a major impact on patients at a professional, social and family level and can lead to a complete inability to carry out any type of everyday activity. For example, patients may have mobility problems, breathing difficulties, cognitive problems, or gradual memory loss.
Neurodegenerative diseases are growing into a global challenge, as medical advances ensure more individuals live longer. Worldwide, at least 55 million people are believed to be living with Alzheimer’s disease or other dementias. If breakthroughs are not discovered, rates could exceed 152 million by 2050. All current therapies for neurodegenerative diseases aim to relieve symptoms and do not target the process of neuron death.

The first sign of RP is usually a loss of night vision, which becomes apparent in childhood. Problems with night vision can make it difficult to navigate in low light. Later, the disease causes blind spots to develop in the side (peripheral) vision. Over time, these blind spots merge to produce tunnel vision. The disease progresses over years or decades to affect central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. In adulthood, many people with retinitis pigmentosa become legally blind.

The typical clinical phenomenon of RP indication is apoptosis of photoreceptor cells, which leads to visual impairment and even blindness. SunRegen is developing innovative drug to prevent and repair photoreceptor apoptosis through an anti-neuronal apoptosis and neuroprotective mechanism, thereby protecting and repairing visual function.

Dry AMD is a common eye disorder among people over 50. It causes blurred or reduced central vision due to the breaking down of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD is a slow deterioration of the cells of the macula, often over many years, as the retinal cells die off and are not renewed. The term ‘dry’ does not mean the person has dry eyes, just that the condition is not wet AMD.

The histopathologic features of dry macular degeneration include atrophy and loss of retinal photoreceptor cells and retinal pigment epithelium, deposition of vitreous warts along the choroidal-retinal interval between the RPE and Bruch's membrane, and accumulation of lipofuscin. SunRegen is developing innovative drug to prevent and repair photoreceptor apoptosis through an anti-neuronal apoptotic mechanism and improve visual function by enhancing lysosomal scavenger protein aggregation and reducing lipofuscin accumulation.